Applied Pharmaceutical Innovation
$21,928,275.00 CAD
- Program
- Life Sciences Fund Contributions
- Recipient country
- Canada
- Fiscal year
- 2025-2026
- Agreement period
- January 13, 2026 – April 30, 2030
- Reference
- ic:033-2025-2026-Q4-515742
Published purpose
API intends to perform the end to end manufacturing of antimicrobial drug products as a demonstration of domestic medicine manufacturing capabilities.
In plain English AI-generated
Funding supports Applied Pharmaceutical Innovation to demonstrate domestic manufacturing of antimicrobial drug products, from end to end, in Canada.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.